Genitourinary Cancers | Specialty

Dr. Grande on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 17th 2019

Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Dr. Lee on the Results of the ENTRATA Trial in Advanced RCC

October 16th 2019

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Dr. Gupta on Challenges of Identifying Biomarkers in Bladder Cancer

October 15th 2019

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

October 9th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Pili on the Challenges of Translocation RCC

October 8th 2019

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

Nivolumab/Tivozanib Combo Shows Promise in mRCC

October 8th 2019

Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.

Dr. Bates on Stimulating the Immune System With Nanoparticles in RCC

October 7th 2019

Paula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.

Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

October 4th 2019

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

Dr. Pal on CRISPR-Based Technology in RCC

October 4th 2019

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Dr. Bhatt on Identification of Immune Checkpoint Pathway in RCC

October 2nd 2019

Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.

Uzzo Shares Insight on Sequencing Surgery in RCC

October 2nd 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.

Dr. Uzzo on the Evolving Role of Surgery in Metastatic Kidney Cancer

October 1st 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer

September 30th 2019

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

September 29th 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

September 29th 2019

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019